UVA1 Phototherapy in Acral Vitiligo

Acral Vitiligo Clinical Trial

Official title:

The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03378011
• Other study ID #: Dermatology 3
• Status: Completed
• Phase: N/A
• First received: December 8, 2017
• Last updated: December 17, 2017
• Start date: November 2015
• Est. completion date: November 2016

Study information

• Verified date: December 2017
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

evaluate the effect of UVA1 phototherapy in the treatment of acral vitiligo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 2016
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Patients with acral vitiligo.

• Patients more than 12 years old.

Exclusion Criteria:

• Patients less than 12 years old.

• Patients with any other skin diseases or autoimmune diseases.

• Patients taking medical treatment or phototherapy for vitiligo.

Related Conditions & MeSH terms

• Acral Vitiligo
• Vitiligo

Intervention

Other:
• phototherapy
phototherapy either UVA1 or topical PUVA on acral vitiligo

Locations

Country	Name	City	State
Egypt	Maha Fathy Elmasry	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	effect of medium dose UVA1 phototherapy in treatment of acral vitiligo	effect of medium dose UVA1 phototherapy in treatment of acral vitiligo using point counting and vitiligo area severity index (VASI) score	1 year